OncoMatch/Clinical Trials/NCT05673148
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Is NCT05673148 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Chemotherapy for metastatic colorectal adenocarcinoma.
Treatment: Chemotherapy — This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: BRAF V600E
No known BRAF V600E mutation
Required: MSH2 wild-type
No known microsatellite instable (MSI) tumor
Required: MSH6 wild-type
No known microsatellite instable (MSI) tumor
Required: MLH1 wild-type
No known microsatellite instable (MSI) tumor
Required: PMS2 wild-type
No known microsatellite instable (MSI) tumor
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — first-line for metastatic disease
Patients must be receiving (or have received) first-line systemic therapy for metastatic disease for a minimum of 16 weeks (4 months) and a maximum of 24 weeks (6 months)
Lab requirements
Blood counts
ANC >= 1,500/mm^3; Platelet count >= 50,000/mm^3
Kidney function
Creatinine <= 1.5 x ULN OR calculated creatinine clearance >= 30 mL/min (Cockcroft-Gault equation)
Liver function
Total bilirubin <= 1.5 x ULN; AST/ALT <= 3.0 x ULN (<= 5 x ULN if metastatic liver disease)
ANC >= 1,500/mm^3; Platelet count >= 50,000/mm^3; Creatinine <= 1.5 x ULN OR calculated creatinine clearance >= 30 mL/min; Total bilirubin <= 1.5 x ULN; AST/ALT <= 3.0 x ULN (<= 5 x ULN if metastatic liver disease)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Kingman Regional Medical Center · Kingman, Arizona
- Mayo Clinic Hospital in Arizona · Phoenix, Arizona
- Tower Cancer Research Foundation · Beverly Hills, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, California
- Cedars Sinai Medical Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify